Professionals 217 Users Online

Fibroblast Growth Factors Market

Market Study on Fibroblast Growth Factors: Substantial Application in Cell Culture Expected

Fibroblast Growth Factors Market Segmented By Application such as Bone Disorders, Pancreatic Cancer, Cancer Pain, Achondroplasia, Burns wounds, Spinal cord injuries

Fibroblast Growth Factors Market Outlook (2023 to 2033)

In 2022, the global fibroblast growth factors market was valued at US$ 261.1 million. By the end of 2033, the market is predicted to reach US$ 582.9 million, expanding at a CAGR of 7.6% over the next ten years.

Fibroblast growth factors (FGFs) exert substantial control over the processes of cellular proliferation and differentiation. They hold pivotal significance in, wound healing, tissue maintenance, normal development, and angiogenesis in somatic stem cells. Mutations in FGF genes are linked to a diverse spectrum of disorders, encompassing conditions like cancer, heart disease, degenerative joint disease, diabetes, Parkinson's disease, and low levels of phosphate in the blood.

FGFs are often studied in cells in a dish (in vitro), so making sure that they remain stable and effective inside the body (in vivo) is important. Scientists have come up with materials and carriers, like special delivery systems, to help FGFs work better and last longer when used in living organisms. These systems have shown promising results in experiments.

  • FGF2 accounted for a market share of 21.2% in 2022.
  • Revenue from fibroblast growth factors accounted for 13.3% share of the global growth factors market in 2022.

The potential of FGFs is extensively challenged in medical treatments. By using these growth factors along with stem cells and special materials, chances of regeneration and healing of tissues like skin, muscles, tendons, bones, teeth, and nerves can be increased. This could open the door to new ways of helping the body recover from injuries or diseases.

Attribute Key Insights

Fibroblast Growth Factors Market Size (2022)

US$ 261.1 Million

Projected Market Value (2033)

US$ 582.9 Million

Global Market Growth Rate (2023 to 2033)

7.6% CAGR

Market Share of Top 5 Countries (2022)


Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

What’s Raising the Importance of Fibroblast Growth Factors in the Medical Space?

In-depth Understanding of Wound Healing Mechanisms and Advancements in Molecular Science

Wound healing poses an ongoing therapeutic perplex within the medical community, given the intricacies involved in assessing and managing wounds. This involves navigating a complex process influenced by several factors critical to the healing journey.

Tissue injury is a common denominator across all medical specialties. Wound healing, regardless of the tissue involved, follows a consistent sequence of events. A comprehensive grasp of this sequence, the involved cells, their timing, and the molecular signals involved can lead to optimizing patient care in a significant way.

Remarkable progress has been achieved in comprehending the intricate mechanisms of wound healing. Advancements in molecular science have enabled modern medicine to gain a profound understanding of the intricate interactions between cells during different phases of wound healing. As the comprehension of growth factors deepens, the future of patient care is expected to encompass scar-free wound healing and transplantation of tissues cultivated from stem cell precursors.

Increasing research and development in this field is likely to open up new prospects for the application of fibroblast growth factors, thus providing market players with lucrative growth opportunities.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can the Sales Growth of Fibroblast Growth Factors Be Negatively Impacted?

“High Cost Associated with Development and Production of FGFs

The intricate process of developing and producing FGFs entails substantial financial implications that underscore the complex nature of modern medical research and biotechnology. While the potential benefits of FGFs in various therapeutic applications are undeniable, the high costs associated with their development and production pose significant challenges that necessitate careful consideration.

The initial research phase involves in-depth investigations into FGFs' molecular mechanisms, interactions, and potential applications. These studies often require specialized equipment, skilled personnel, and extensive resources. Subsequent preclinical testing aims to assess FGFs' safety and efficacy, necessitating comprehensive studies on animal models, further contributing to the financial burden.

The pinnacle of FGF development lies in conducting rigorous clinical trials to validate their therapeutic potential in human subjects. These trials, spanning multiple phases, involve substantial investments in patient recruitment, medical monitoring, data analysis, and regulatory compliance. The costs escalate as trials progress, and the potential for unexpected challenges or setbacks further emphasizes the financial risk. These challenges are expected to hinder the growth of the market.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Country-wise Insights

How is the Fibroblast Growth Factors Market Shaping Up in the United States?

“Growing Demand for Fibroblast Growth Factors Due to Rising Cancer Cases”

The United States accounted for a 94.2% share of the North American fibroblast growth factors market in 2022.

The United States is witnessing a notable rise in the occurrence of diverse carcinomas, which is fueling sales of approved human epidermal growth factor receptor (HER2) inhibitors, thus presenting significant avenues for advancement among market participants. The elevated prevalence of breast and stomach cancer notably contributes to the demand for FGFs.

  • According to the American Society of Clinical Oncology (ASCO) projections for 2023 in the United States, 297,790 women are anticipated to be diagnosed with invasive breast cancer and 55,720 women with non-invasive (in situ) breast cancer. Notably, there has been a gradual increase in the incidence of invasive breast cancer among women, growing by approximately 0.5% annually since the mid-2000s.
  • The American Cancer Society's data for 2022 indicates around 26,500 fresh instances of stomach cancer, with 15,930 occurring in men and 10,570 in women. Tragically, this form of cancer claimed about 11,130 lives, affecting 6,690 men and 4,440 women.

Escalating need for fibroblast growth factors and cytokines in the treatment landscape of various carcinomas and the mounting government initiatives aimed at fostering research endeavors in the country collectively drive the demand for fibroblast growth factors in the United States.

What is the Demand Projection for Fibroblast Growth Factors in Germany?

“Collaborations among Academia, Biotech Companies, and Government Bodies Fueling Demand for FGFs”

Germany accounted for 9% share of the global market in 2022.

Germany stands at the forefront of pioneering advancements in biotechnology and cell culture techniques, with a distinct focus on the transformative potential of fibroblast growth factors (FGFs). This nation's commitment to scientific excellence and innovation has led to remarkable strides in the fields of biotechnology and regenerative medicine.

In the realm of regenerative medicine, Germany's advancements in FGF-based approaches are paving the way for groundbreaking treatments. Researchers are exploring how FGFs can stimulate the regeneration of damaged tissues, potentially revolutionizing the treatment of conditions such as chronic wounds, musculoskeletal disorders, and even neurological ailments.

Strong partnerships between academia, biotech companies, and government bodies facilitate the translation of research into real-world applications. The nation's investment in research infrastructure and funding initiatives, such as the Bioeconomy International program, further catalyze innovation in FGF-related biotechnologies. This makes Germany a prominent market for players looking out for opportunities in the fibroblast growth factors market.

How is the Fibroblast Growth Factors Market Evolving in China?

“Focus on Collaborative Research Initiatives and Expansion of Pharmaceutical Industry”

China held 2.2% share of the global market in 2022. FGFs are emerging as promising therapeutic targets in the treatment of solid tumors within the context of China's burgeoning oncology landscape. FGFs, pivotal signaling molecules, play a crucial role in tumor growth, angiogenesis, and metastasis, making them attractive candidates for innovative cancer therapies.

In China, researchers and clinicians are recognizing the significance of FGFs as potential targets for disrupting the tumor microenvironment and inhibiting cancer progression. By targeting FGF signaling pathways, they aim to impede tumor angiogenesis, thereby limiting the blood supply crucial for tumor sustenance and growth. This approach holds immense potential for curbing tumor expansion and enhancing the efficacy of existing treatment modalities.

China's robust biopharmaceutical industry and collaborative research initiatives have facilitated the exploration of FGF-targeted therapies. Clinical trials and preclinical studies are underway to evaluate the safety and efficacy of FGF inhibitors in various solid tumors, including breast, lung, and gastrointestinal cancers.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Category-wise Insights

Why is FGF2 Most Widely Adopted across the World?

“Extensive Adoption of FGF2 Driven by its Simple Structure and Well-Defined Signaling Pathways”

FGF2 occupied 21.2% share of the global market in 2022. FGF2 has gained popularity due to its broad range of biological activities and applications in various fields. It is one of the most extensively studied and characterized members of the FGF family, contributing to its widespread recognition and utilization.

The relatively simple structure and well-understood signaling pathways of FGF2 have facilitated its study and manipulation in research and therapeutic contexts. Its interactions with cell surface receptors are well-documented, making it a more accessible target for experimental and clinical interventions.

How is Cell Culture Playing a Part in This Business?

“Crucial Role of FGFs in Enhancing Accurate Representation of Cellular Responses and Behaviors Driving Their Demand for Stem Cell Culture”

Cell culture accounted for 27.7% share of the market in 2022. FGFs hold significant importance in cell culture due to their pivotal role in regulating various cellular processes.

FGFs are particularly valuable in stem cell culture, where they help preserve the pluripotency and self-renewal of regenerative cells. Furthermore, FGFs guide cell differentiation, enabling researchers to direct stem cells toward specific lineages for tissue engineering and regenerative medicine applications. In studies ranging from cancer research to drug development, FGFs contribute to the accurate representation of cellular responses and behaviors, providing insights into complex biological phenomena.

Why Do Pharmaceutical & Biotechnology Companies Account for a Prominent Market Share Globally?

“Pharmaceutical and Biotech Companies’ Focus on Targeted Treatments and Clinical Trials Contributing to Increased Utilization of FGFs”

By end user, pharmaceutical and biotechnology companies accounted for 47.8% share of the global market in 2022.

The diverse range of medical conditions that FGFs can address, from wound healing to neurodegenerative disorders and cancer treatment, aligns with the industry's mission to offer targeted and effective treatments for a spectrum of diseases. FGFs are gaining significant attention from pharmaceutical and biotechnology companies.

Adaptability of FGFs in clinical trials further solidifies their appeal, positioning them as a compelling asset for biopharmaceutical companies seeking to drive medical innovation, meet unmet medical needs, and remain competitive in a dynamic healthcare landscape.

Competition Landscape

The fibroblast growth factors industry is consolidated, with few competitors offering products and services on a global level. To meet end users’ expectations and fortify their consumer base, these companies implement strategies like increased research and development efforts, product launches, and mergers.

  • On October 7, 2021, Abcam, a leading innovator in life sciences reagents and tools, successfully finalized the acquisition of BioVision.
  • On August 4, 2022, Thermo Fisher, as part of its ongoing efforts in the US$ 650 million bioprocessing enhancement initiative, announced a significant step forward by unveiling a US$ 76 million expansion at one of its United States sites.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies manufacturing fibroblast growth factors, which are available in the full report.

Fibroblast Growth Factors Industry Report Scope

Attribute Details

Forecast Period

2023 to 2033

Historical Data Available for

2017 to 2022

Market Analysis

US$ Million for Value

Key Countries Covered

  • United States
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • United Kingdom
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Benelux
  • India
  • Indonesia
  • Thailand
  • Malaysia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • Türkiye
  • South Africa
  • Northern Africa

Key Market Segments Covered

  • Product
  • Application
  • End User
  • Region

Key Companies Covered

  • Thermo Fisher Scientific
  • Sigma-Aldrich (now part of Merck KGaA)
  • PeproTech
  • R&D Systems (a Bio-Techne brand)
  • Abcam
  • Cell Signaling Technology
  • Novus Biologicals

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments of Fibroblast Growth Factors Industry Research


  • FGF1
  • FGF2
  • FGF3
  • FGF4
  • FGF7
  • FGF10
  • FGF11
  • FGF12
  • FGF13
  • FGF14
  • FGF15
  • FGF18
  • FGF19
  • FGF20
  • FGF23
  • Others


  • Oncology
  • Hematology
  • Wound Healing
  • Dermatology
  • Cardiovascular Disease & Diabetes
  • Cell Culture
  • Others

End User:

  • Pharmaceutical & Biotechnology Companies
  • Research Centers & Academic Institutes
  • CMOs & CDMOs


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

- Companies Covered in This Report -

  • Thermo Fisher Scientific
  • Sigma-Aldrich (now part of Merck KGaA)
  • PeproTech
  • R&D Systems (a Bio-Techne brand)
  • Abcam
  • Cell Signaling Technology
  • Novus Biologicals

- Frequently Asked Questions -

The global fibroblast growth factors market was valued at US$ 261.1 million in 2022.

Sales of fibroblast growth factors increased at 7.1% CAGR from 2017 to 2022.

The United States accounted for 94.2% share of the North American market in 2022.

The market for fibroblast growth factors in Germany reached US$ 23.4 million in 2022.

China held 2.2% share of the global fibroblast growth factors market in 2022.

FGF2 held a leading market share of 21.2% in 2022.

The United States, United Kingdom, Germany, India, and Japan held 62.2% market share in 2022.

The global market for fibroblast growth factors is set to reach US$ 582.9 million by 2033.

Thermo Fisher Scientific, Sigma-Aldrich, PeproTech, and R&D Systems are key players in this market.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate